So when Stephen Bloom's paper came out in January of 1996, and he was the first one to call GLP-1 a neurotransmitter, I think, but I was already way into actually screening these kind of molecules that later then became liraglutide
[1] [3] Understanding these multisystem effects is essential when evaluating potential adverse effects, including fatigue, as the widespread distribution of GLP-1 receptors means these medications influence numerous physiological processes beyond glucose metabolism
Multiple drugs within this class have been approved for T2D management since the mid-2000s
doi: 10.1056/NEJMoa1603827
For patients who have experienced facial volume loss and skin quality changes alongside body laxity, a common presentation in GLP-1 patients, incorporating Restorative Skin Complex into the daily routine amplifies the results of in-clinic facial treatments and provides continuous regenerative support between sessions
Once again, semaglutide demonstrates a higher performance compared with liraglutide, although individual medical status must be assessed before the prescription of this treatment to prevent side effects